small molecule

FORTOVASE

SAQUINAVIR

Loss of exclusivityloss of exclusivity
CompanyHOFFMANN LA ROCHE INC

Drug detail

Brand nameFORTOVASE
Active ingredientSAQUINAVIR
Strength200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalNovember 1997
Marketing statusDISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

FORTOVASE patent cliff — loss of exclusivity — | CliffBio